Eli Lilly reported that its oral GLP-1 candidate orforglipron surpassed Novo Nordisk’s Rybelsus in a Phase 3 diabetes trial, lowering HbA1c more and producing greater weight loss. The highest dose of orforglipron lowered A1C by 1.9 percentage points versus 1.5 for Rybelsus, along with 8.2% versus 5.3% weight loss. Lilly plans a regulatory filing based on these data while continuing to generate obesity and diabetes efficacy evidence. Meanwhile, regulatory and promotional pressures on GLP-1 therapies mount.